方法对比

	系统性红斑狼疮活动性医生总体评估 (PGA)	强直性脊柱炎疾病活动度评分 (BASDAI)	28关节疾病活动度评分 (DAS28)
领域	风湿病学	风湿病学	风湿病学
方法族	Process / pipeline	Process / pipeline	Process / pipeline
起源年份	1992	1994	1995
提出者	Bombardier et al.	Garrett et al.	Prevoo et al.
类型	Clinician-rated	Patient-reported outcome (PRO)	Clinician-rated
开创性文献	Petri M. Thermodynamic instability in the pathogenesis of lupus nephritis. Nat Rev Rheum. 2016;12(11):635-642.	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.
别名	Physician Global Assessment, PGA-Lupus, Clinician Global Assessment-SLE	BASDAI, BAS-DAI	DAS28, DAS28-CRP, DAS28-ESR
相关	3	4	3
摘要	The Physician Global Assessment (PGA) is a clinician-rated, single-item measure of overall systemic lupus erythematosus (SLE) disease activity on a visual analogue scale (0–10). Used alongside structured indices like SLEDAI, PGA captures the clinician's integrated judgment of SLE severity, synthesising clinical examination, serology, imaging, and organ-specific findings into a holistic activity score. PGA is simple, practical, and widely used in SLE research and clinical practice as a complementary measure that reflects experienced clinician assessment of disease state.	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.